Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.

"Disclosure Professor Dr Gwo Fuang Ho reports grants and/or nonfinancial support from Eli Lily, Regeneron, MSD, AB Science, Astellas, Tessa Therapeutics, and Arcus Bioscience, grants and personal fees from Roche, Boehringer Ingelheim, and Janssen Pharmaceuticals, grants, personal fees, and nonfinancial support from AstraZeneca, Pfizer, and Ipsen, personal fees from Bristol Myers Squibb, and nonfinancial support from Taiho outside the submitted work. Dr Harissa H Hasbullah reports personal fees from MSD and AstraZeneca and grants from Novartis and Roche outside the submitted work. Dr Lye Mun Tho reports personal fees from Novartis, Pfizer, Roche, AstraZeneca, and Bristol Myers Squibb outside the submitted work. The authors report no other conflicts of interest in this work."

"This work was supported by the Malaysian Thoracic Society."